Get the Stockscreener App
36.66
2.91%
-1.10
After Hours:
36.70
0.04
+0.11%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $36.66, with a volume of 33.96M.
It is down -2.91% in the last 24 hours and down -27.12% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$37.76
Open:
$36.37
24h Volume:
33.96M
Relative Volume:
1.50
Market Cap:
$162.95B
Revenue:
$46.77B
Net Income/Loss:
$15.45B
P/E Ratio:
10.57
EPS:
3.468
Net Cash Flow:
$4.40B
1W Performance:
-5.00%
1M Performance:
-27.12%
6M Performance:
-35.39%
1Y Performance:
-58.98%
1-Day Range:
$35.85
$36.95
1-Week Range:
$35.85
$38.24
52-Week Range:
$35.85
$91.90
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
36.66 | 167.84B | 46.77B | 15.45B | 4.40B | 3.468 |
|
LLY
Lilly Eli Co
|
1,007.73 | 909.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.75 | 599.00B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
233.86 | 414.21B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
164.18 | 318.41B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
201.76 | 315.94B | 58.80B | 10.24B | 8.98B | 3.2788 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Upgrade | Jefferies | Underperform → Hold |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Dec-08-25 | Downgrade | Argus | Buy → Hold |
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Election of employee representatives to the Board of Directors of Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya - Finviz
Novo Nordisk A/S (NVO) and Vivtex Corporation Announce a Partnership - Finviz
Novo Nordisk Sales Warning Tests GLP-1 Reliance And Future Growth Story - Sahm
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk's Shares Drop 16.43% on CagriSema Setback and Legal Scrutiny Trading Volume Slides to 184th - Bitget
Jim Cramer Recommends Eli Lilly over Novo Nordisk - Finviz
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - Sahm
Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment - Finviz
European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize
Ozempic Price War - Benzinga
CagriSema Trial Miss Leaves Novo Nordisk Obesity Outlook Under Scrutiny - Sahm
Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight - Sahm
Novo Nordisk: Another Disappointing Cagrisema Trial Adds Pressure to High-Dose Strategy - Morningstar
Novo Nordisk Is Losing Share, but We Still See Its Portfolio and Pipeline Supporting a Wide Moat - Morningstar
Stock Of The Day: Breakdown In Novo Nordisk? - Finviz
Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal agains - The Economic Times
Pre-market Overview | Uncertainty looms over US tariff policy! All three major futures indices trend lower; popular Chinese ADRs active in pre-market trading, with PDD Holdings up over 3%; Novo-Nordisk A/S plunges 14% as its next-generation weight-loss dr - 富途牛牛
Novo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly's in trial - CNBC
Does Novo Nordisk A s (b Shares) Adrhedged stock benefit from AI growthQuarterly Profit Review & AI Powered Buy/Sell Recommendations - mfd.ru
Novo Nordisk stock forecast: Analysts mixed on Q4 earnings & 2026 guidance - Capital.com
Glucagon-like Peptide 1 (GLP-1) Market Report 2026-2035: Market to Reach $33.26 Billion by 2030 - GlobeNewswire Inc.
EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients - Finviz
Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - GlobeNewswire Inc.
Novo Nordisk Balances Oral Wegovy Launch With Legal Fight On Compounds - Sahm
Novo Nordisk Faces Legal And FDA Challenges As Valuation Gap Widens - Sahm
FDA Crackdown Reshapes Wegovy Competition And Risks For Novo Nordisk Investors - Sahm
Can Novo Nordisk A s (b Shares) Adrhedged outperform in the next rallyIPO Watch & Safe Capital Growth Stock Tips - mfd.ru
Where is Novo Nordisk A/S (NVO) Headed? - Finviz
Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside - Sahm
Novo Nordisk Takes Legal Action Against Hims & Hers Over Wegovy Knock Offs - Sahm
Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending - Finviz
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):